Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 357 followers
Latest posts
Last updated 2 days ago
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
2 days ago
With this approval, Roche’s automated mass spectrometry platform now offers the industry’s...
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
3 days ago
Giredestrant is the only oral SERD to show superior invasive disease-free survival...
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
4 days ago
The new PCR test aids in the diagnosis of infectious causes of...
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
4 days ago
Approval based on phase II NOBILITY and phase III REGENCY studies showing...
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
4 days ago
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed...
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
5 days ago
Overall survival was twice as long for people treated with Columvi in...
Reminder: Invitation to Roche’s Virtual Oncology/SABCS Investor Event
9 days ago
We are pleased to invite investors and analysts to participate in our...
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
11 days ago
The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare...
Invitation to Roche’s Virtual Oncology/SABCS Investor Event
17 days ago
We are pleased to invite investors and analysts to participate in our...
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
24 days ago
Lunsumio provides high rates of deep and long-lasting responses in third-line and...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
25 days ago
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
about 1 month ago
The first (FENhance 2) of two pivotal RMS studies met its primary...